Clinical Trials

156 enrolled 20 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Lymphoma

NCT04875195 2025-10-29

MK-3475-B68

Phase 2 Completed

66 enrolled 16 charts

Hodgkin Disease

NCT03884556 2025-07-02

TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers

GastrointestinalGenitourinaryLymphoidThoracic

56 enrolled 19 charts

Urinary Bladder Neoplasms, Lung Neoplasms, Lymphoma, Neoplasms, Pancreatic Neoplasms

NCT04317066 2025-04-06

KEYNOTE-A33

7 enrolled 13 charts

BreastGastrointestinalHead & NeckLymphoidSarcomaThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Lymphoma, B-Cell

NCT03058289 2025-02-27

IT-01

Phase 1/2 Completed

111 enrolled 21 charts

Diabetes Mellitus, Insulin-Dependent, 12, Bile Duct Neoplasms, Breast Neoplasms, Carcinoma, Carcinoma, Squamous Cell, Colonic Neoplasms, Head and Neck Neoplasms, Liver Neoplasms, Lung Neoplasms, Lymphoma, Neoplasms, Pancreatic Neoplasms, Sarcoma

NCT03674567 2025-01-24

Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination with Pembrolizumab

Phase 1/2 Completed

323 enrolled

BreastGenitourinaryGynecologicHead & NeckLymphoidThoracic

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Lymphoma

NCT03922204 2024-12-11

A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies

72 enrolled

Lymphoma, B-Cell

NCT02453594 2024-10-29

Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087)

Phase 2 Completed

211 enrolled 22 charts

Hodgkin Disease

NCT03340766 2024-10-17

HARBOUR

31 enrolled 29 charts

Phase 1 Active not recruiting

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05878691 2024-07-22

A Study of GRC 54276 in Participants With Advanced Solid Tumors and Lymphomas.

320 enrolled

Lymphoma

NCT03934814 2024-07-01

Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and Lymphoma

98 enrolled

Phase EARLY_PHASE1 Recruiting

Lymphoma

NCT04541108 2024-04-18

Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies

15 enrolled

DermatologicHead & NeckLymphoidSarcoma

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Lymphoma, Melanoma, Sarcoma

NCT03329950 2024-03-28

A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

132 enrolled

Bile Duct Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Esophageal Neoplasms, Fallopian Tube Neoplasms, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Laryngeal Neoplasms, Liver Neoplasms, Lung Neoplasms, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Mouth Neoplasms, Oropharyngeal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Cholangiocarcinoma, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Hyper-IgM Immunodeficiency Syndrome

NCT04920383 2024-03-01

NEON-2

29 enrolled

Lymphoma

NCT04609579 2024-01-30

Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma

GastrointestinalGynecologicLymphoid

27 enrolled

Bites and Stings, Lymphoma, Ovarian Neoplasms, Colorectal Neoplasms, Lymphoma, B-Cell

NCT03454451 2023-12-21

CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers

BreastGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidSarcomaThoracic

117 enrolled

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Sarcoma, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05296772 2023-09-06

Phase 1 First-in-human Study of JS014

Phase 1 Unknown

60 enrolled

Lymphoma, Neoplasms, Neoplasms, Experimental

NCT02376699 2023-05-01

Safety Study of SEA-CD40 in Cancer Patients

DermatologicHead & NeckLymphoidThoracic

159 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Hodgkin Disease, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Neoplasm Metastasis, Neoplasms, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Neoplasms, Squamous Cell

NCT03841110 2023-05-01

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

37 enrolled

Breast Neoplasms, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Melanoma, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT04920617 2023-04-07

VITALIZE

Phase 2 Recruiting

102 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT03815682 2022-12-06

RPTR-147 in Patients With Selected Solid Tumors and Lymphomas

23 enrolled

DermatologicLymphoid

Lymphoma, Melanoma

NCT03630159 2022-08-15

PORTIA

12 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Lymphoma, Large B-Cell, Diffuse

NCT02178722 2022-02-14

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

Phase 1/2 Completed

444 enrolled 19 charts

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Microsatellite Instability, Triple Negative Breast Neoplasms

NCT01953692 2021-08-04

MK-3475-013

LymphoidMyeloidPlasma cell

197 enrolled 52 charts

Hodgkin Disease, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Lymphoma, Large B-Cell, Diffuse

NCT02501473 2020-09-09

MK-3475-174

Phase 1/2 Terminated

52 enrolled 23 charts

BreastDermatologicGastrointestinalGenitourinaryGynecologicLymphoidThoracic

Lymphoma, Follicular, Lymphoma, Non-Hodgkin

NCT03544723 2020-06-09

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

Phase 2 Unknown

40 enrolled

Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Hodgkin Disease, Liver Neoplasms, Lymphoma, Melanoma, Stomach Neoplasms, Carcinoma, Merkel Cell, Neoplasms, Squamous Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT03471351 2019-12-27

Safety and Efficacy Study of Tenalisib (RP6530) in Combination With Pembrolizumab in Relapsed or Refractory cHL

2 enrolled

Hodgkin Disease

NCT02665650 2019-05-16

Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

30 enrolled

Hodgkin Disease

NCT01986426 2018-10-03

LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab